Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.16 | -1.89% | -0.08 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -1.89% | |
| New 52 Week Closing Low | Bearish | -1.89% |
| Alert | Time |
|---|---|
| Possible NR7 | about 14 hours ago |
| New 52 Week Low | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Down 3% | about 18 hours ago |
| Fell Below Lower Bollinger Band | about 18 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/07/2024
Eagle Pharmaceuticals, Inc. Description
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Organic Chemistry Chronic Lymphocytic Leukemia Lymphocytic Leukemia Angioplasty Percutaneous Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.4 |
| 52 Week Low | 4.05 |
| Average Volume | 146,418 |
| 200-Day Moving Average | 10.25 |
| 50-Day Moving Average | 5.41 |
| 20-Day Moving Average | 4.71 |
| 10-Day Moving Average | 4.56 |
| Average True Range | 0.39 |
| RSI (14) | 37.89 |
| ADX | 15.81 |
| +DI | 14.48 |
| -DI | 22.04 |
| Chandelier Exit (Long, 3 ATRs) | 4.22 |
| Chandelier Exit (Short, 3 ATRs) | 5.23 |
| Upper Bollinger Bands | 5.28 |
| Lower Bollinger Band | 4.13 |
| Percent B (%b) | 0.02 |
| BandWidth | 24.28 |
| MACD Line | -0.27 |
| MACD Signal Line | -0.25 |
| MACD Histogram | -0.0211 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.46 | ||||
| Resistance 3 (R3) | 4.46 | 4.35 | 4.41 | ||
| Resistance 2 (R2) | 4.35 | 4.28 | 4.36 | 4.39 | |
| Resistance 1 (R1) | 4.26 | 4.23 | 4.21 | 4.26 | 4.38 |
| Pivot Point | 4.15 | 4.15 | 4.13 | 4.16 | 4.15 |
| Support 1 (S1) | 4.06 | 4.08 | 4.01 | 4.06 | 3.94 |
| Support 2 (S2) | 3.95 | 4.03 | 3.96 | 3.93 | |
| Support 3 (S3) | 3.86 | 3.95 | 3.91 | ||
| Support 4 (S4) | 3.86 |
